SCHEMBL1320962

SCHEMBL1320962

O=C(C=Cc1ccc(C=CC(=O)c2ccccc2Br)cc1)NO

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.72
LMNA P02545 3/20 0.72
TP53 P04637 2/20 0.72
HDAC2 Q92769 10/20 0.64
HDAC3 O15379 9/20 0.64
HDAC1 Q13547 9/20 0.64
HDAC8 Q9BY41 9/20 0.64
HDAC4 P56524 8/20 0.64
HDAC6 Q9UBN7 8/20 0.64
HDAC7 Q8WUI4 7/20 0.64
HDAC10 Q969S8 7/20 0.64
HDAC11 Q96DB2 7/20 0.64
HDAC9 Q9UKV0 7/20 0.64
HDAC5 Q9UQL6 7/20 0.64
EGFR P00533 1/20 0.53
MAPT P10636 4/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
KDM4E B2RXH2 1/20 0.51
MEN1 O00255 1/20 0.51
CYP3A4 P08684 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1320961 1.00 ALDH1A1 (0.72) ALDH1A1LMNATP53HDAC2HDAC3
SCHEMBL14692643 0.86 ALDH1A1 (0.76) ALDH1A1LMNATP53HDAC2HDAC3
SCHEMBL29429080 0.86 ALDH1A1 (0.76) ALDH1A1LMNATP53HDAC2HDAC3
SCHEMBL14692644 0.86 ALDH1A1 (0.76) ALDH1A1LMNATP53HDAC2HDAC3
SCHEMBL25265248 0.85 TP53 (0.74) ALDH1A1LMNATP53MAPTSMN1; SMN2
SCHEMBL30384879 0.85 TP53 (0.74) ALDH1A1LMNATP53MAPTSMN1; SMN2
SCHEMBL25216133 0.85 TP53 (0.74) ALDH1A1LMNATP53MAPTSMN1; SMN2
SCHEMBL28571268 0.84 ALDH1A1 (1.00) ALDH1A1LMNATP53EGFRMAPT
SCHEMBL5451151 0.84 ALDH1A1 (0.72) ALDH1A1LMNATP53MAPTSMN1; SMN2
SCHEMBL5451154 0.84 ALDH1A1 (0.72) ALDH1A1LMNATP53MAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1814850-B9 NEW HISTONE DEACETYLASES INHIBITORS DAC SRL (IT) 2015-02-25 EP claimed
EP-1814850-B1 NEW HISTONE DEACETYLASES INHIBITORS DAC SRL (IT) 2013-07-03 EP claimed
CN-101039905-B New Histone Deacetylase Inhibitors DAC S.R.L. (IT) 2012-02-08 CN claimed
US-8058273-B2 Histone deacetylases inhibitors DAC S.R.L. (IT) 2011-11-15 US claimed
US-7803800-B2 Histone deacetylases inhibitors DAC S.R.L. (IT) 2010-09-28 US claimed
US-20100240660-A1 NEW HISTONE DEACETYLASES INHIBITORS DAC S.R.L. (IT) 2010-09-23 US claimed
US-20080096889-A1 Histone Deacetylases Inhibitors GENEXTRA S.P.A. (IT) 2008-04-24 US claimed
CN-101039905-A New Histone Deacetylase Inhibitors DAC SRL (IT) 2007-09-19 CN claimed
EP-1814850-B9 NEW HISTONE DEACETYLASES INHIBITORS DAC SRL (IT) 2015-02-25 EP disclosed
EP-1814850-B1 NEW HISTONE DEACETYLASES INHIBITORS DAC SRL (IT) 2013-07-03 EP disclosed
US-8058273-B2 Histone deacetylases inhibitors DAC S.R.L. (IT) 2011-11-15 US disclosed
US-7803800-B2 Histone deacetylases inhibitors DAC S.R.L. (IT) 2010-09-28 US disclosed
US-20100240660-A1 NEW HISTONE DEACETYLASES INHIBITORS DAC S.R.L. (IT) 2010-09-23 US disclosed
US-20080096889-A1 Histone Deacetylases Inhibitors GENEXTRA S.P.A. (IT) 2008-04-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100240660-A1 NEW HISTONE DEACETYLASES INHIBITORS HDAC1, HDAC3, HDAC11 ALDH1A1 358/4885LMNA 895/4885TP53 610/4885
US-20080096889-A1 Histone Deacetylases Inhibitors HDAC1, HDAC3, HDAC11 ALDH1A1 370/4885LMNA 712/4885TP53 595/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.